289 related articles for article (PubMed ID: 23463262)
1. Chitosan-modified PLGA nanoparticles with versatile surface for improved drug delivery.
Wang Y; Li P; Kong L
AAPS PharmSciTech; 2013 Jun; 14(2):585-92. PubMed ID: 23463262
[TBL] [Abstract][Full Text] [Related]
2. PLGA nanoparticles for the oral delivery of 5-Fluorouracil using high pressure homogenization-emulsification as the preparation method and in vitro/in vivo studies.
Li X; Xu Y; Chen G; Wei P; Ping Q
Drug Dev Ind Pharm; 2008 Jan; 34(1):107-15. PubMed ID: 18214762
[TBL] [Abstract][Full Text] [Related]
3. Development and in vitro evaluation of surface modified poly(lactide-co-glycolide) nanoparticles with chitosan-4-thiobutylamidine.
Grabovac V; Bernkop-Schnürch A
Drug Dev Ind Pharm; 2007 Jul; 33(7):767-74. PubMed ID: 17654025
[TBL] [Abstract][Full Text] [Related]
4. Novel docetaxel chitosan-coated PLGA/PCL nanoparticles with magnified cytotoxicity and bioavailability.
Badran MM; Alomrani AH; Harisa GI; Ashour AE; Kumar A; Yassin AE
Biomed Pharmacother; 2018 Oct; 106():1461-1468. PubMed ID: 30119220
[TBL] [Abstract][Full Text] [Related]
5. Modification of the release characteristics of estradiol encapsulated in PLGA particles via surface coating.
Enayati M; Stride E; Edirisinghe M; Bonfield W
Ther Deliv; 2012 Feb; 3(2):209-26. PubMed ID: 22834198
[TBL] [Abstract][Full Text] [Related]
6. Improved mucoadhesion and cell uptake of chitosan and chitosan oligosaccharide surface-modified polymer nanoparticles for mucosal delivery of proteins.
Dyawanapelly S; Koli U; Dharamdasani V; Jain R; Dandekar P
Drug Deliv Transl Res; 2016 Aug; 6(4):365-79. PubMed ID: 27106502
[TBL] [Abstract][Full Text] [Related]
7. Chitosan-modified PLGA nanoparticles tagged with 5TR1 aptamer for in vivo tumor-targeted drug delivery.
Taghavi S; Ramezani M; Alibolandi M; Abnous K; Taghdisi SM
Cancer Lett; 2017 Aug; 400():1-8. PubMed ID: 28412238
[TBL] [Abstract][Full Text] [Related]
8. Characterization of rabies pDNA nanoparticulate vaccine in poloxamer 407 gel.
Bansal A; Wu X; Olson V; D'Souza MJ
Int J Pharm; 2018 Jul; 545(1-2):318-328. PubMed ID: 29746999
[TBL] [Abstract][Full Text] [Related]
9. PLGA Microparticles Entrapping Chitosan-Based Nanoparticles for the Ocular Delivery of Ranibizumab.
Elsaid N; Jackson TL; Elsaid Z; Alqathama A; Somavarapu S
Mol Pharm; 2016 Sep; 13(9):2923-40. PubMed ID: 27286558
[TBL] [Abstract][Full Text] [Related]
10. Surface modification of PLGA nanoparticles with biotinylated chitosan for the sustained in vitro release and the enhanced cytotoxicity of epirubicin.
Chen H; Xie LQ; Qin J; Jia Y; Cai X; Nan W; Yang W; Lv F; Zhang QQ
Colloids Surf B Biointerfaces; 2016 Feb; 138():1-9. PubMed ID: 26638176
[TBL] [Abstract][Full Text] [Related]
11. Fabrication and Use of Poly(d,l-lactide-co-glycolide)-Based Formulations Designed for Modified Release of 5-Fluorouracil.
Leelakanok N; Geary S; Salem A
J Pharm Sci; 2018 Feb; 107(2):513-528. PubMed ID: 29045885
[TBL] [Abstract][Full Text] [Related]
12. Preparation, characterization, and in vitro and in vivo investigation of chitosan-coated poly (d,l-lactide-co-glycolide) nanoparticles for intestinal delivery of exendin-4.
Wang M; Zhang Y; Feng J; Gu T; Dong Q; Yang X; Sun Y; Wu Y; Chen Y; Kong W
Int J Nanomedicine; 2013; 8():1141-54. PubMed ID: 23658482
[TBL] [Abstract][Full Text] [Related]
13. Long-acting inhalable chitosan-coated poly(lactic-co-glycolic acid) nanoparticles containing hydrophobically modified exendin-4 for treating type 2 diabetes.
Lee C; Choi JS; Kim I; Oh KT; Lee ES; Park ES; Lee KC; Youn YS
Int J Nanomedicine; 2013; 8():2975-83. PubMed ID: 23976850
[TBL] [Abstract][Full Text] [Related]
14. Biological evaluation of 5-fluorouracil nanoparticles for cancer chemotherapy and its dependence on the carrier, PLGA.
Nair K L; Jagadeeshan S; Nair SA; Kumar GS
Int J Nanomedicine; 2011; 6():1685-97. PubMed ID: 21980233
[TBL] [Abstract][Full Text] [Related]
15. Comparison of sorafenib-loaded poly (lactic/glycolic) acid and DPPC liposome nanoparticles in the in vitro treatment of renal cell carcinoma.
Liu J; Boonkaew B; Arora J; Mandava SH; Maddox MM; Chava S; Callaghan C; He J; Dash S; John VT; Lee BR
J Pharm Sci; 2015 Mar; 104(3):1187-96. PubMed ID: 25573425
[TBL] [Abstract][Full Text] [Related]
16. Understanding the adsorption mechanism of chitosan onto poly(lactide-co-glycolide) particles.
Guo C; Gemeinhart RA
Eur J Pharm Biopharm; 2008 Oct; 70(2):597-604. PubMed ID: 18602994
[TBL] [Abstract][Full Text] [Related]
17. Chitosan-Coated Poly(lactic-co-glycolic acid)-Diiodinated boron-Dipyrromethene Nanoparticles Improve Tumor Selectivity and Stealth Properties in Photodynamic Cancer Therapy.
Voon SH; Tiew SX; Kue CS; Lee HB; Kiew LV; Misran M; Kamkaew A; Burgess K; Chung LY
J Biomed Nanotechnol; 2016 Jul; 12(7):1431-52. PubMed ID: 29336539
[TBL] [Abstract][Full Text] [Related]
18. A Novel Method for Preparing Surface-Modified Fluocinolone Acetonide Loaded PLGA Nanoparticles for Ocular Use: In Vitro and In Vivo Evaluations.
Salama AH; Mahmoud AA; Kamel R
AAPS PharmSciTech; 2016 Oct; 17(5):1159-72. PubMed ID: 26589410
[TBL] [Abstract][Full Text] [Related]
19. Comparative studies on chitosan and polylactic-co-glycolic acid incorporated nanoparticles of low molecular weight heparin.
Yang T; Nyiawung D; Silber A; Hao J; Lai L; Bai S
AAPS PharmSciTech; 2012 Dec; 13(4):1309-18. PubMed ID: 23054983
[TBL] [Abstract][Full Text] [Related]
20. Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: effects of surfactants on particles size, characteristics and in vitro performance.
Liu Y; Pan J; Feng SS
Int J Pharm; 2010 Aug; 395(1-2):243-50. PubMed ID: 20472049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
